Skip to content
    AHR
    Earnings call· Jun 2026(Q2 FY26)

    American Healthcare REIT Q2 FY26 earnings call AHR

    Aug 7, 2026 Source

    Executive summary

    American Healthcare REIT Q2 FY26 — Strong Performance Drives Increased Full-Year Guidance and Significant Acquisition Activity

    American Healthcare REIT delivered a robust second quarter, marked by strong organic growth and significant acquisition momentum, leading to a material increase in full-year guidance. The company is actively scaling its platform, leveraging deep operator relationships and disciplined underwriting to capitalize on generational investment opportunities in the senior housing sector, while also navigating a leadership transition with Jeff Hanson assuming the CEO role.

    Highlights

    5
    • Total portfolio same-store NOI grew 13.2% year-over-year for the tenth consecutive quarter.

    • Normalized FFO per diluted share increased 28.6% year-over-year to $0.54 in Q2 FY26.

    • Full-year NFFO per diluted share guidance was raised to a range of $2.15 to $2.19, representing ~26% growth over 2025.

    • Net debt to EBITDA improved to 2.5x, a 0.5 turn better than Q1 FY26.

    • Closed over $1.4 billion in new acquisitions year-to-date, with an additional $800 million in the pipeline.

    Concerns

    2
    • Trilogy's skilled nursing occupancy stepped down 70 basis points sequentially in Q2 FY26.

    • Senior housing occupancy experienced typical first-half seasonality, with a slight pullback of 50 basis points from Q1 FY26.

    Guidance & targets

    6
    CategoryTargetConfidence
    Normalized FFO per diluted share
    $2.15 to $2.19
    high materiality
    High
    Total portfolio same-store NOI growth
    11% to 13%
    high materiality
    High
    Integrated senior health campuses same-store NOI growth
    13% to 16%
    medium materiality
    High
    SHOP same-store NOI growth
    18% to 21%
    high materiality
    High
    Outpatient medical same-store NOI growth
    Flat to up 1%
    low materiality
    Medium
    Triple net leased properties same-store NOI growth
    2% to 3% increase
    low materiality
    Medium

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Total Portfolio
    Same-store NOI growth for the tenth consecutive quarter.
    13.2%4.9%
    Integrated Senior Health Campuses (Trilogy)
    Set a new post-pandemic high watermark for same-store NOI margin. Occupancy held bucking usual first half seasonality, with strength in senior housing offsetting skilled nursing dip.
    Same-store occupancy: 90.7%Skilled nursing occupancy (sequential change): -70 bpsSenior housing occupancy: 91.9%Senior housing occupancy (sequential change): FlatSenior housing occupancy (YoY change): +200 bpsSame-store operating expenses (sequential change): -0.9%Controllable costs (sequential change): -4.6%Quality mix: 75.5% of resident days
    16.1%5.4%21.1%
    SHOP
    Strong results driven by widening spread between RevPAR and ExPOR, leading to significant margin expansion. Occupancy continues to grow year-over-year.
    Same-store NOI margin (YoY expansion): 242 bpsRevPAR (sequential change): +1.4%ExPOR (sequential change): -0.8%
    20.5%9.9%22.3%

    Operational metrics

    16
    Normalized FFO per diluted share
    $0.54up 28.6% YoY
    Q2 FY26
    Normalized FFO per diluted share
    $1.05up 31.3% YoY
    YTD FY26
    Cash NOI
    31%
    YoY

    Year-over-year increase, combining organic growth and accretion from acquisitions.

    Net debt to EBITDA
    2.5x0.5 turn better than Q1 FY26, 1.2 turns better than Q2 FY25
    Q2 FY26
    Equity capital raised
    $1.5B
    Q2 FY26 and subsequent
    Unsettled forward sale agreements
    $631M
    as of 2026-08-07

    Represents a powerful funding source for the pipeline.

    Revolving credit facility capacity
    $800Mfully available
    as of 2026-08-07
    Med Advantage rate growth
    8.4%
    YoY

    Achieved by optimizing mix and partnerships.

    Acquisition initial yields
    mid-5s to low 6s
    Q2 FY26

    For high-quality institutional-grade assets.

    Acquisition stabilized yields
    7% or above
    future

    Expected stabilization for acquired assets.

    Average occupancy of value-add acquisitions
    82%
    Q2 FY26

    For value-add assets in the pipeline.

    Average occupancy of stabilized acquisitions
    low 90s
    Q2 FY26

    For stabilized assets in the pipeline, still representing operating leverage.

    Average age of acquired assets
    2019 vintage
    YTD FY26

    Includes $1.4B closed YTD and $800M in pipeline.

    SHOP asset average age
    21 yearsdropped from 29 years
    Q2 FY26

    Significant improvement in a very rapid period.

    Trilogy properties with excess land for expansion
    ~30
    Q2 FY26

    Provides multi-year runway for villa expansions.

    G&A growth rate
    much, much slower ratethan NOI growth
    future

    Investment in platform, people, and technology to support scaling.

    Industry KPIs

    7
    MetricValueDetails
    Exppor growth-0.8%%
    Revpor growth1.4%%
    Senior housing occupancy90.7%%
    Revpor minus exppor spreadwidening
    Operator tenant concentration
    Same store noi growth by segment13.2%%
    Investment volume and sourcing mix$1.4BUSD

    Orderbook & backlog

    2
    Investment pipeline$800MQ2 FY26

    Includes newly awarded deals and deals awarded in Q1 not yet closed. Expected to close most, if not all, before year-end.

    Loan on properties with options to acquire$86.2Mpost Q2 FY26

    Loan on 7 properties with an existing partner, with a defined path to near-term ownership.

    Deals & partnerships

    5
    Existing regional partnerExpansion with existing operators, deepening Southeast presence.$86.4M

    Acquisition of 4 communities in Georgia and South Carolina.

    Existing partnerExpansion with existing operators.$40.5M

    Acquisition of 1 community in Minnesota.

    VariousOpportunistic pruning of noncore assets.$22.3M

    Sale of 3 noncore properties.

    New regional operatorsExpansion into new regions (Northeast) and deepening exposure in existing regions (Southeast).$1B

    Acquisition of 10 additional SHOP communities after quarter end.

    Existing partnerLoan on properties with options to acquire.$86.2M

    Funded a loan on 7 properties with options to acquire them, with a defined path to near-term ownership.

    Capital programs

    3
    Trilogy new campus developmentunderway

    Benefit: 5 campuses

    Five new campuses are currently in construction, part of Trilogy's ongoing development capabilities.

    Trilogy villa expansionsunderway

    Benefit: 5-6 projects per year

    Multi-year runway for villa expansions on existing Trilogy properties with excess land, focused on pre-leasing and derisking.

    Trilogy Legacy Village (Memory Care)underway

    Benefit: 40-unit communities

    Stand-alone memory care villages next to Trilogy main campuses, included in expansion projects.

    Risks & headwinds

    3
    Skilled nursing occupancy declineQ2 FY26

    70 bps sequential decline in Q2 FY26

    Mitigation: Offset by strength in Trilogy's senior housing segment; focus on quality mix (75.5% of resident days) and selective payer sources.

    Senior housing occupancy seasonalityQ2 FY26

    50 bps sequential pullback from Q1 FY26

    Mitigation: Viewed as typical seasonality; starting with higher occupancy into the busiest selling season, which provides more pricing power.

    Cap rate expansion riskQ3-Q4 FY25, Q1 FY26

    Cap rate compression seen late last year

    Mitigation: Cap rates have remained fairly static over the last several months; leveraging off-market deals and disciplined underwriting to maintain yields and acquire high-quality assets below replacement cost.

    What to watch in Q3 FY26

    5

    Trilogy Occupancy & Revenue Management

    next quarter
    CurrentSenior housing occupancy 91.9% (flat QoQ), skilled nursing -70bps QoQ
    TargetContinued sequential growth in occupancy and effective revenue management

    Why it matters

    Indicates demand strength and pricing power, crucial for SHOP margin expansion and overall NOI growth.

    And we're seeing the selling season now in July actually looking pretty strong. And we -- we're ahead of where we were in Q2, ahead of where we started last year at this time, and that provides more pricing power as well.

    Q&A highlights

    6

    What drove the deceleration in controllable costs within Trilogy, and is the sub-2% growth rate sustainable or transitory?

    Gabe Willhite explained that Trilogy's team made expense management a big focus, leading to strong performance. While some seasonality exists (utilities in Midwest), the overall execution on expense control is robust and comes from multiple components, making outperformance on this front achievable.

    That team has shown time and time again that if they focus on something they can really outperform what the expectations will be.

    asked by Michael Stroyeck · answered by Gabriel Willhite

    2 min read6 chapters

    Detailed Narrative

    01

    Leadership Transition and Strategic Vision

    Jeff Hanson, who co-founded the platform 21 years ago, has returned as CEO, emphasizing rapid scaling, disciplined growth, and strengthening the leadership team. He highlighted the company's long-standing strategy, built with Danny Prosky, and the focus on becoming the partner of choice for senior housing operators. The transition was facilitated by a decade-long succession plan, with Gabe Willhite elevated to President and COO, and Scott Estes appointed Lead Independent Director.

    02

    Operational Excellence and Margin Expansion

    The company achieved double-digit same-store NOI growth for the tenth consecutive quarter, driven by strong performance in both Trilogy and SHOP segments. Trilogy set a new post-pandemic high for same-store NOI margin at 21.1%, benefiting from effective expense control (controllable costs down 4.6% sequentially) and quality mix improvement (75.5% of resident days). SHOP expanded its same-store NOI margin by 242 bps YoY to 22.3%, with RevPAR rising 1.4% and ExPOR decreasing 0.8% sequentially.

    03

    Aggressive Capital Allocation and Acquisition Strategy

    AHR closed over $1.4 billion in acquisitions year-to-date, with an additional $800 million in the pipeline, none of which is reflected in current guidance. The strategy focuses on high-quality, institutional-grade assets in infill markets, often sourced off-market through existing operator relationships. Acquisitions are typically below replacement cost, with initial yields in the mid-5s to low 6s, stabilizing to 7% or above. The average age of the $2.2 billion in referenced acquisitions is 2019 vintage, significantly improving the portfolio's overall age.

    04

    Balance Sheet Strength and Funding Capacity

    Net debt to EBITDA improved to 2.5x for Q2 FY26, a significant reduction from 3x in Q1 FY26 and 1.2 turns better than Q2 FY25. The company raised approximately $1.5 billion in equity capital in Q2 FY26 and subsequent, with $631 million in unsettled forward sale agreements providing a powerful funding source for the pipeline. This strong financial position, coupled with an $800 million fully available revolving credit facility, enables offensive pursuit of attractive opportunities.

    05

    Platform Enhancement and Operator Support

    AHR is investing ahead of growth by adding depth in asset management, clinical oversight, and underwriting. The revenue management, analytics, and reporting tools developed with Trilogy are being extended to more SHOP operators, enhancing capabilities for partners. The company hosts innovation forums for 11 operators, fostering best practices and ensuring new acquisitions land with operators meeting AHR's standards.

    06

    Trilogy's Development Pipeline and Market Position

    Trilogy continues to execute on its development plan, with 5 new campuses under construction and a multi-year runway for villa expansions and other modular additions on approximately 30 existing properties with excess land. This organic growth channel is expected to contribute to future performance, with strong pre-leasing and performance meeting underwriting expectations. Trilogy's Med Advantage rate growth was 8.4% YoY on a same-store basis, demonstrating effective optimization of payer mix.

    AI-generated summary of the company’s earnings call. Not investment advice.